During the Spring Festival in 2020, the new coronavirus (2019 ncov) has a rapid outbreak across the country, and the market is shrouded in the haze of the epidemic. Stirred by the pneumonia epidemic caused by the new coronavirus, the A-share market showed significant differentiation.
The first financial reporter found that the scientific and technological innovation board stocks rising today are mainly in the biomedical industry, most of which are related to epidemic prevention. Shuoshi biology developed a new coronavirus nucleic acid detection kit and a general-purpose coronavirus nucleic acid detection kit on January 13. On the evening of February 2, shuoshi biology announced that it planned to donate a new coronavirus nucleic acid detection kit and instrument with a cumulative value of 10 million yuan to the disease control system and medical institutions for the detection of new coronavirus and other coronaviruses.
Coincidentally, the new coronavirus (2019 ncov) nucleic acid detection kit (PCR fluorescence probe method) was developed by thermocline on January 20.
According to the public information, Jiete biology is mainly engaged in the research, development, production and sales of disposable plastic consumables for cell culture and related liquid treatment biological laboratories. Its main products include disposable plastic consumables for biological culture and liquid treatment biological laboratories, with a small amount of reagents, small experimental instruments, etc. The companys mask business is mainly operated by its subsidiary Guangzhou baifei air purification materials Co., Ltd. (hereinafter referred to as baifei). In 2016, 2017, 2018 and January June 2019, baifeis operating revenues were 2.4693 million yuan, 2.1749 million yuan, 3319 million yuan and 102000 yuan respectively, accounting for 1.99%, 1.3%, 0.16% and 0.11% of Jiete biologicals operating revenues.
On the evening of February 3, Jiete biological said that during the outbreak, baifels mask business capacity was greatly affected by the limitation of material supply, and the recovery of production was uncertain. Due to the limited number of masks produced, the impact on the performance of this year is expected to be limited. In the long run, the mask business has no significant impact on the companys business performance.
On January 28, Borui medicine donated 1 million yuan to the epidemic area through Wuhan red cross society as a special fund to fight the new coronavirus pneumonia epidemic.
Although the first trading day after the Spring Festival was a tragic one, there was a market view that the scientific and technological innovation board might have the property of risk aversion.
The disclosure period of 2019 annual report is coming. According to wind statistics, there are 44 science and Technology Innovation Board Companies in total who have made forecast on the profit situation in 2019, 32 companies have increased in advance and 7 companies have decreased in advance. Among them, 21 companies reported a year-on-year increase of more than 50% in net profit attributable to the parent company, and 30 companies reported a year-on-year increase of more than 20%. Compared with the growth enterprise market, 32% of the enterprises with a year-on-year growth of more than 50% in the net profit of the parent company, 57% of the enterprises with a year-on-year growth of more than 20%, and 39% of the enterprises with a negative share.
In the research report, Zhongtai Securities said that scientific and technological innovation companies with medical and biopharmaceutical properties may have thematic investment opportunities. High quality companies in the science and technology innovation board are limited by the impact of epidemic haze in the medium and long-term hard science and technology support and development policies, while relatively overvalued technology stocks or risk preference reduction are mistakenly killed.
In addition, from the perspective of thematic investment, through the resumption of SARS event in 2003, the relative cumulative excess return rate of the pharmaceutical sector in the outbreak period (2003 / 04 / 16 ~ 2003 / 04 / 30) is the highest, which is 7.21%, far higher than other consumer sectors. In the future, once controlled, the market will soon return to rationality after a short-term panic. It is expected that companies with biopharmaceutical properties or chemical properties will benefit from thematic investment opportunities under the outbreak.
According to the Guangfa strategy, referring to the experience of SARS, the impact of the epidemic on cycle and consumer stocks is far greater than that of science and technology growth stocks, and science and technology innovation board may be limited. In addition, with reference to the early August 2019, under the change of Sino-U.S. relations, the scientific and technological innovation board as an incremental market has a certain risk aversion attribute, and the excess return is far superior to other global large-scale assets.
In terms of positions, by the fourth quarter of 2019 (Q4), there were 70 scientific and technological innovation boards listed in total, with the overall public funds holding 2.66% of the outstanding shares of scientific and technological innovation board and the market value holding 4.95% of the current market value. The new generation information technology industry has 31 listed companies, with the average shareholding ratio of public funds of 4.02% ranking first, followed by the pharmaceutical industry of 2.29%.
The Shanghai Stock Exchange issued a notice on full support of regulatory business arrangements related to the prevention and control of new coronavirus infection and pneumonia. From February 3, the time limit for the review of the initial public listing of the science and technology innovation board, the review of major asset restructuring of listed companies and the time limit for the issuer to reply to other relevant reviews, as well as the time limit for the issuer to update its financial report, shall be suspended; the specific time for the recovery of the calculation will be notified separately according to the situation of epidemic prevention and control. Up to now, there are 209 enterprises in science and technology innovation board, 60 of which have been inquired, 3 have been suspended for deliberation, 8 have been approved at the municipal Party committee meeting, 12 have been submitted for registration, 92 have been effective in registration, 2 have been suspended and 25 have been terminated. The number of reported science and technology innovation board funds has reached 132, including 10 equity funds and 122 hybrid funds. Of the 132, 131 received one feedback and one correction notice. Source: First Financial Editor: Guo Chenqi, nbj9931
The Shanghai Stock Exchange issued a notice on full support of regulatory business arrangements related to the prevention and control of new coronavirus infection and pneumonia. From February 3, the time limit for the review of the initial public listing of the science and technology innovation board, the review of major asset restructuring of listed companies and the time limit for the issuer to reply to other relevant reviews, as well as the time limit for the issuer to update its financial report, shall be suspended; the specific time for the recovery of the calculation will be notified separately according to the situation of epidemic prevention and control.